Ten reasons why it is worth to use ramipril Review article
Article Sidebar
Published:
Jun 30, 2015
Keywords:
ramipril, arterial hypertension, cardiovascular risk, prevention
Main Article Content
Abstract
Hypertension is an important risk factor, causing almost half of coronary events and strokes. According to current guidelines, when deciding to start antihypertensive therapy the most important is to estimate total cardiovascular risk associated with degree of hypertension and quantity and type of concomitant risk factors. Contemporary antihypertensive treatment is not just about obtaining permanent normotension while maintaining a good quality of life, but also for the correction of hemodynamic and metabolic disorders, and above all – to prolong life by reducing morbidity and mortality from coronary events, heart failure and stroke. In most patients with hypertension and coexisting various disorders or high risk for cardiovascular complications, renin–angiotensin–aldosterone blocking agents may represent the most appropriate choice. Ramipril plays a significant role in patients with coronary disease or multiple risk factors considering its outstanding cardiac and vasoprotective properties.
Article Details
How to Cite
Barylski , M. (2015). Ten reasons why it is worth to use ramipril. Medycyna Faktow (J EBM), 8(2(27), 59-65. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2313
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. The Heart Outcome Prevention Evaluation Study Investigators: Effect of angiotensin-converting enzyme, ramipril on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000; 342: 145-153.
2. HOPE/HOPE-TOO Study Investigators: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112(9): 1339-1346.
3. Heart Outcomes Prevention Evaluation Study Investigators: Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
4. The DREAM Trial Investigators: Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 2006; 355: 1551-1562.
5. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
6. Hall A.S., Murray G.D., Ball S.G. on behalf of the AIREX Study Investigators: Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997; 349: 1493-1497.
7. Pfeffer M.A., Greaves S.C., Arnold J.M. et al.: Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997; 95(12): 2643-2651.
8. Kjoller-Hansen L., Steffensen R., Grande P.: The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J. Am. Coll. Cardiol. 2000; 35(4): 881-888.
9. Lièvre M., Guéret P., Gayet C. et al.; HYCAR Study Group: Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. Hypertension 1995; 25(1): 92-97.
10. Agabiti-Rosei E., Ambrosioni E., Dal Palu C. et al.: ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (Ramipril Cardioprotective Evaluation) study on behalf of the RACE study group. J. Hypertens. 1995; 13: 1325-1334.
11. Lonn E., Yusuf S., Dzavik V. et al.; SECURE Investigators: Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103(7): 919-925.
12. Ruggenenti P., Perna A., Gherardi G. et al.: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-364.
13. Ramipril – charakterystyka produktu leczniczego.
14. Yusuf S., Teo K.K., Pogue J. et al.; The ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-1559.
15. Fox K.M.; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782-788.
16. Braunwald E., Domanski M.J., Fowler S.E. et al.; PEACE Trial Investigators: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 2004; 351(20): 2058-2068.
17. Rouleau J.L., Warnica W.J., Baillot R. et al.; IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators: Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation 2008; 117(1): 24-31.
18. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2015; 1(1): 1-70.
19. Wienbergen H., Schiele R., Gitt A.K. et al.; MITRA PLUS Study Group: Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. Am. J. Cardiol. 2002; 90(10): 1045-1049.
20. Pilote L., Abrahamowicz M., Rodrigues E. et al.: Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann. Intern. Med. 2004; 141 (2): 102-112.
21. Cleland J.G., Erhardt L., Murray G. et al.: Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur. Heart. J. 1997; 18(1): 41-51.
22. Arnold J.M., Yusuf S., Young J. et al.; HOPE Investigators: Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107(9): 1284-1290.
23. Szczepańska-Sadowska E., Cudnoch-Jędrzejewska A.: Fizjologia i patofizjologia układu renina–angiotensyna. W: Januszewicz A., Januszewicz W., Rużyłło W. (red.): Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Medycyna Praktyczna, Kraków 2005: 23-62.
24. Enseleit F., Lüscher T.F., Ruschitzka F.: Angiotensin-converting enzyme inhibition and endothelial dysfunction: focus on ramipril. Eur. Heart J. 2003 (supl. A); 5: A31-A36.
25. Mathew J., Sleight P., Lonn E. et al.; Heart Outcomes Prevention Evaluation (HOPE) Investigators: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104(14): 1615-1621.
2. HOPE/HOPE-TOO Study Investigators: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112(9): 1339-1346.
3. Heart Outcomes Prevention Evaluation Study Investigators: Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
4. The DREAM Trial Investigators: Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 2006; 355: 1551-1562.
5. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828.
6. Hall A.S., Murray G.D., Ball S.G. on behalf of the AIREX Study Investigators: Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997; 349: 1493-1497.
7. Pfeffer M.A., Greaves S.C., Arnold J.M. et al.: Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997; 95(12): 2643-2651.
8. Kjoller-Hansen L., Steffensen R., Grande P.: The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J. Am. Coll. Cardiol. 2000; 35(4): 881-888.
9. Lièvre M., Guéret P., Gayet C. et al.; HYCAR Study Group: Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. Hypertension 1995; 25(1): 92-97.
10. Agabiti-Rosei E., Ambrosioni E., Dal Palu C. et al.: ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (Ramipril Cardioprotective Evaluation) study on behalf of the RACE study group. J. Hypertens. 1995; 13: 1325-1334.
11. Lonn E., Yusuf S., Dzavik V. et al.; SECURE Investigators: Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103(7): 919-925.
12. Ruggenenti P., Perna A., Gherardi G. et al.: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359-364.
13. Ramipril – charakterystyka produktu leczniczego.
14. Yusuf S., Teo K.K., Pogue J. et al.; The ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-1559.
15. Fox K.M.; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782-788.
16. Braunwald E., Domanski M.J., Fowler S.E. et al.; PEACE Trial Investigators: Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 2004; 351(20): 2058-2068.
17. Rouleau J.L., Warnica W.J., Baillot R. et al.; IMAGINE (Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme) Investigators: Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation 2008; 117(1): 24-31.
18. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2015; 1(1): 1-70.
19. Wienbergen H., Schiele R., Gitt A.K. et al.; MITRA PLUS Study Group: Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction. Am. J. Cardiol. 2002; 90(10): 1045-1049.
20. Pilote L., Abrahamowicz M., Rodrigues E. et al.: Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann. Intern. Med. 2004; 141 (2): 102-112.
21. Cleland J.G., Erhardt L., Murray G. et al.: Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur. Heart. J. 1997; 18(1): 41-51.
22. Arnold J.M., Yusuf S., Young J. et al.; HOPE Investigators: Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107(9): 1284-1290.
23. Szczepańska-Sadowska E., Cudnoch-Jędrzejewska A.: Fizjologia i patofizjologia układu renina–angiotensyna. W: Januszewicz A., Januszewicz W., Rużyłło W. (red.): Inhibitory konwertazy angiotensyny w leczeniu chorób układu sercowo-naczyniowego. Medycyna Praktyczna, Kraków 2005: 23-62.
24. Enseleit F., Lüscher T.F., Ruschitzka F.: Angiotensin-converting enzyme inhibition and endothelial dysfunction: focus on ramipril. Eur. Heart J. 2003 (supl. A); 5: A31-A36.
25. Mathew J., Sleight P., Lonn E. et al.; Heart Outcomes Prevention Evaluation (HOPE) Investigators: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104(14): 1615-1621.